source
- Swiss startup Vaderis raises $152 million to fund Phase 3 trial of rare bleeding disorder therapyVaderis Therapeutics, a 13‑person Swiss biotech, announced a $152 million Series B financing round aimed at advancing its experimental therapy into a Phase 3 study. The company is testing a treatm…
- FDA issues early alert after BD needle set defects linked to four deathsThe FDA’s Center for Devices and Radiological Health released an early alert warning clinicians to stop using Becton Dickinson’s intraosseous vascular access needle sets after reports of serious in…